Heteroarylphenoxy benzamide kappa opioid ligands

US10316021B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Natasha Mariam Kablaoui · Newton, US
• Michael Eric Green · Boston, US
• Justin Ian Montgomery · Ledyard, US
• Michael Aaron Brodney · East Lyme, US
• Patrick Robert Verhoest · Newton, US
• Gregory Wayne Kauffman · East Greenwich, US
• Danica Antonia Rankic · New London, US
• Scot Richard Mente · Arlington, US
• Bruce N. Rogers · Belmont, US
• Kapildev Kashmirilal Arora · Niantic, US
• Matthew Francis Dunn · Middletown, US

Key dates

• Filing date: Nov 22, 2017
• Grant date: Jun 11, 2019
• Expiry date: Jan 11, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.